January 2026 Research Update

This month added clearer, real-world reminders that VEXAS can look like other conditions at first, and that certain blood and bone marrow clues can help point people toward the right diagnosis. Across reports, genetic testing for a UBA1 change was the key step that confirmed VEXAS when symptoms and blood counts looked like other inflammatory or bone marrow disorders. A registry comparison also suggested a few clinical differences that may help separate VEXAS from Schnitzler's syndrome in men who have skin symptoms. [1] [2]

In a registry study comparing men with VEXAS versus Schnitzler's syndrome (both with skin involvement), VEXAS was more strongly signaled by older age when symptoms began and by swollen lymph nodes. Lower blood counts also leaned toward VEXAS in the simpler comparisons, including anemia and a lack of high white blood cell counts, while low platelets showed a possible signal in the more detailed analysis. This kind of pattern may help explain why some people are first labeled with a different inflammatory diagnosis before VEXAS is considered. [2]

Several case reports showed how VEXAS can initially resemble a bone marrow disorder such as myelodysplastic syndrome, especially when macrocytic anemia is present. In these reports, bone marrow findings such as vacuolization (little empty-looking spaces in developing blood cells) together with a UBA1 mutation confirmed the diagnosis. This reinforces that diagnosis often relies on putting symptoms, blood counts, bone marrow appearance, and genetic testing together rather than any single feature alone. [1] [3]

For patients and caregivers, the main update is about recognition rather than new treatments: this month highlighted concrete features that have helped real people get to the correct diagnosis. The registry study suggests that among men with skin symptoms, factors like age at symptom start and lymph node swelling may raise suspicion for VEXAS compared with Schnitzler's syndrome, but these are not definitive by themselves. The case reports underline that UBA1 testing and bone marrow review can be central when anemia or MDS-like features are part of the picture, while also showing that diagnostic paths can be complex and individualized. This evidence is mainly early and observational, so it helps clarify patterns but cannot guarantee how any one person will present. [2] [1] [3]

This month did not bring large treatment trials, but it did add several detailed patient stories that illustrate how different treatment approaches are being used and what can happen during care. Across these reports, inflammation-targeting medicines (including JAK inhibitors and steroids) were described alongside blood-disease treatments such as azacitidine when VEXAS overlaps with bone marrow disorders. A few reports also highlighted safety events that may matter for future research, including a possible medicine-related swelling reaction and a serious bacterial infection in an immunosuppressed patient. [4] [5] [6]

Two separate case reports described JAK inhibitors (ruxolitinib and tofacitinib), each paired with steroids, in different VEXAS situations. One patient with myocarditis-related heart rhythm block recovered heart conduction within days after ruxolitinib was added, and heart imaging later showed improvement. Another patient with a different UBA1 mutation had rapid clearing of skin disease after starting tofacitinib plus low-dose steroid, with improvement described over 7 months. [4] [7]

Several reports involved therapies used when VEXAS overlaps with bone marrow disease, showing both diagnostic complexity and possible side effects to watch for in research. Azacitidine was started in a patient whose early picture looked like myelodysplastic syndrome, but specific outcomes from the treatment were not provided in the summary. In another patient receiving 5-azacitidine, one-sided tongue swelling (angioedema) occurred during treatment, improved with a short course of corticosteroids, and did not return with later cycles; the authors reported that whether the drug caused the event was uncertain. [1] [5]

Infection risk appeared in one case report describing Vibrio vulnificus bloodstream infection in a patient receiving tocilizumab and glucocorticoids, with the infection resolving after antibiotic treatment. The authors noted iron overload from transfusions as a possible contributing factor in that individual. This single case cannot show how often this happens, but it adds a concrete example of the kinds of complications that can occur in heavily treated patients. [6]

For patients, these reports mainly add real-world context about the range of treatments being tried and the kinds of outcomes doctors are documenting, rather than proving that one option works best. The JAK inhibitor reports are early, single-patient signals that targeted anti-inflammatory treatment may help specific problems like skin inflammation or inflammation-related heart involvement, but they do not predict what will happen for others. The azacitidine and 5-azacitidine reports emphasize that VEXAS care can overlap with treatment for bone marrow disorders, and they raise questions about possible side effects that need more than one case to understand. The infection case shows that serious infections can occur during immune-suppressing treatment, but the evidence here is limited to one person and does not define risk for everyone. [4] [7] [1] [5] [6]

A case series this month made eye involvement in VEXAS feel more concrete by describing what orbital inflammation can look like across multiple patients. The overall pattern was that eyelid swelling and eye pain were common, and most people kept normal vision over time. A smaller number had severe one-sided vision loss linked to intense local complications, showing that eye symptoms can range from uncomfortable to serious. [8]

In this 14-person series of men with VEXAS and orbital inflammation, eyelid swelling was reported in all patients and eye pain in about 7 out of 10. Vision was described as generally normal and stable, with no posterior eye involvement reported. Two patients had severe vision loss in one eye due to orbital compartment syndrome or periorbital necrotizing fasciitis, and one patient died from VEXAS-related complications during follow-up. [8]

For patients, this series helps clarify that eye and orbit symptoms in VEXAS often involve visible swelling and pain, but do not automatically mean permanent vision loss. It also shows that a minority of patients can have very severe eye complications, which may be important for future research on monitoring and rapid evaluation of new eye symptoms. Because this is a case series without a comparison group, it cannot estimate how common these problems are in all people with VEXAS, but it provides a clearer picture of what has been observed in real patients. [8]